phrykt

Bicycle Therapeutics Plc (BCYC): who owns it and who trades it

As of Nov 16, 2026, BCYC insiders reported 48 open-market sales worth $522K and no purchases in the last 12 months, with 13% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Lee (CEO), with $239K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Bicycle Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BCYC

104 funds and institutions reported BCYC shares worth $159M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 36.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Baker Bros. Advisors LP36.2%
Fcpm III Services B.v.11.5%
Armistice Capital, LLC11.3%
Long Focus Capital Management, LLC11.0%
Acadian Asset Management LLC6.6%
Renaissance Technologies LLC5.1%
GSK plc5.1%
T. Rowe Price Associates3.0%
Marshall Wace, LLP2.7%
Qube Research & Technologies Ltd2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP10.89M36.23%$46.2MNo change
Fcpm III Services B.v.3.47M11.54%$14.7MNo change
Armistice Capital, LLC3.40M11.31%$14.4MNo change
Long Focus Capital Management, LLC3.31M11.02%$14MNo change
Acadian Asset Management LLC1.97M6.55%$8.3MNo change
Renaissance Technologies LLC1.53M5.10%$6.5M+57%
GSK plc1.53M5.09%$6.5MNo change
T. Rowe Price Associates902,1503.00%$3.8M-12%
Marshall Wace, LLP797,9402.66%$3.4M+111%
Qube Research & Technologies Ltd775,5672.58%$3.3M+151%
Morgan Stanley667,2692.22%$2.8M+8%
Schroder Investment Management Group615,8332.05%$2.6MNo change
Citadel Advisors LLC554,2251.84%$2.3M+47%
Millennium Management LLC553,9671.84%$2.3M+95%
Peapod Lane Capital LLC537,9781.79%$2.3M+344%
Diadema Partners LP462,7241.54%$2M-3%
Two Sigma Investments, LP434,5771.45%$1.8M+164%
Jane Street Group, LLC392,1631.31%$1.7M+80%
Flax Pond Capital, LLC376,2221.25%$1.7M+114%
Birchview Capital, LP313,6161.04%$1.3M-32%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BCYC insiders reported $0 of open-market purchases and $522K of sales. 13% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$522K
48 trades, 8 people
Sales under a 10b5-1 plan
13%
Share of sale value
Latest trade
Oct 5, 2026
Filed Oct 7, 2026

Purchases and sales by month

$328K$328KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 5, 2026Jennifer Scott PerryChief Operating OfficerSale plan30$3.57$107Form 4
Oct 5, 2026Michael SkynnerCHIEF SCIENTIFIC OFFICERSale503$3.57$1.8KForm 4
Oct 5, 2026Kevin LeeCEOSale1,638$3.57$5.8KForm 4
Oct 5, 2026Travis Alvin ThompsonCFOSale79$3.57$282Form 4
Oct 5, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale242$3.57$864Form 4
Oct 5, 2026Jennifer Scott PerryChief Operating OfficerSale plan80$3.56$285Form 4
Oct 5, 2026Jennifer Scott PerryChief Operating OfficerSale plan326$3.78$1.2KForm 4
Oct 2, 2026Michael SkynnerCHIEF SCIENTIFIC OFFICERSale1,942$3.47$6.7KForm 4
Oct 2, 2026Kevin LeeCEOSale6,167$3.47$21.4KForm 4
Oct 2, 2026Travis Alvin ThompsonCFOSale893$3.47$3.1KForm 4
Oct 2, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale1,572$3.47$5.5KForm 4
Oct 2, 2026Robert Charles SwantonDirectorSale3,431$3.47$11.9KForm 4
Oct 2, 2026Jennifer Scott PerryChief Operating OfficerSale plan1,094$3.47$3.8KForm 4
Jul 6, 2026Jennifer Scott PerryChief Operating OfficerSale plan333$4.34$1.4KForm 4
Jul 6, 2026Jennifer Scott PerryChief Operating OfficerSale plan43$4.31$185Form 4
Jul 6, 2026Michael SkynnerCHIEF SCIENTIFIC OFFICERSale532$4.31$2.3KForm 4
Jul 6, 2026Kevin LeeCEOSale1,737$4.31$7.5KForm 4
Jul 6, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale255$4.31$1.1KForm 4
Jul 6, 2026Travis Alvin ThompsonCFOSale104$4.31$448Form 4
Jul 2, 2026Jennifer Scott PerryChief Operating OfficerSale plan1,036$4.27$4.4KForm 4
Jul 2, 2026Michael SkynnerCHIEF SCIENTIFIC OFFICERSale1,859$4.27$7.9KForm 4
Jul 2, 2026Kevin LeeCEOSale5,905$4.27$25.2KForm 4
Jul 2, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale1,506$4.27$6.4KForm 4
Jul 2, 2026Travis Alvin ThompsonCFOSale819$4.27$3.5KForm 4
Apr 6, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale251$5.05$1.3KForm 4
Apr 6, 2026Travis Alvin ThompsonCFOSale102$5.05$515Form 4
Apr 6, 2026Jennifer Scott PerryChief Operating OfficerSale plan37$5.05$187Form 4
Apr 6, 2026Jennifer Scott PerryChief Operating OfficerSale plan333$5.04$1.7KForm 4
Apr 6, 2026Kevin LeeCEOSale1,716$5.05$8.7KForm 4
Apr 6, 2026Michael SkynnerCHIEF SCIENTIFIC OFFICERSale525$5.05$2.7KForm 4
Apr 2, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale1,521$4.91$7.5KForm 4
Apr 2, 2026Travis Alvin ThompsonCFOSale799$4.91$3.9KForm 4
Apr 2, 2026Jennifer Scott PerryChief Operating OfficerSale plan1,038$4.91$5.1KForm 4
Apr 2, 2026Kevin LeeCEOSale5,967$4.91$29.3KForm 4
Apr 2, 2026Michael SkynnerCHIEF SCIENTIFIC OFFICERSale1,879$4.91$9.2KForm 4
Jan 5, 2026Travis Alvin ThompsonCHIEF ACCOUNTING OFFICERSale1,115$6.45$7.2KForm 4
Jan 5, 2026Michael SkynnerCHIEF TECHNOLOGY OFFICERSale3,266$6.46$21.1KForm 4
Jan 5, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale2,367$6.45$15.3KForm 4
Jan 5, 2026Alistair MilnesCHIEF OPERATING OFFICERSale3,416$6.46$22.1KForm 4
Jan 5, 2026Alethia YoungCFOSale plan1,878$6.54$12.3KForm 4
Jan 5, 2026Alethia YoungCFOSale plan2,456$6.45$15.8KForm 4
Jan 5, 2026Kevin LeeCEOSale10,989$6.46$71KForm 4
Jan 2, 2026Travis Alvin ThompsonCHIEF ACCOUNTING OFFICERSale1,317$6.80$9KForm 4
Jan 2, 2026Michael SkynnerCHIEF TECHNOLOGY OFFICERSale3,045$6.80$20.7KForm 4
Jan 2, 2026Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAISale2,827$6.80$19.2KForm 4
Jan 2, 2026Alistair MilnesCHIEF OPERATING OFFICERSale3,244$6.80$22.1KForm 4
Jan 2, 2026Alethia YoungCFOSale plan3,289$6.80$22.4KForm 4
Jan 2, 2026Kevin LeeCEOSale10,325$6.80$70.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin LeeCHIEF EXECUTIVE OFFICER, Director–$239KOct 5, 2026
Michael SkynnerCHIEF TECHNOLOGY OFFICER–$72.4KOct 5, 2026
Michael Charles Ferguson HannayCHIEF PROD & SUPPLY CHAIN OFF–$57.1KOct 5, 2026
Alethia YoungChief Financial Officer–$50.5KJan 5, 2026
Alistair MilnesCHIEF OPERATING OFFICER–$44.1KJan 5, 2026
Travis Alvin ThompsonCHIEF ACCOUNTING OFFICER–$27.9KOct 5, 2026
Jennifer Scott PerryChief Operating Officer–$18.4KOct 5, 2026
Robert Charles SwantonDirector–$11.9KOct 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BCYC short interest

3.86M BCYC shares are sold short. Over the last 12 reports the number of shares short went up 43%.

As of Oct 30, 2026, 3.86M BCYC shares were sold short, up 11.7% from the report before. At the average daily volume of 460,266 shares, buying them all back would take about 8.4 trading days (days to cover).

Shares short

3.86MMay 15Oct 304.03M

Days to cover

8.4May 15Oct 3015.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.86M–+12%460,2668.4
Oct 15, 20263.45M–+5%554,3326.2
Sep 30, 20263.30M–-1%378,5708.7
Sep 15, 20263.33M–+2%499,1326.7
Aug 31, 20263.28M–+2%238,34313.8
Aug 14, 20263.22M–+8%315,91910.2
Jul 31, 20262.98M–No change301,8539.9
Jul 15, 20262.98M–+3%388,1937.7
Jun 30, 20262.88M–+2%606,6094.8
Jun 15, 20262.83M–-1%648,6414.4
May 29, 20262.86M–+6%264,67110.8
May 15, 20262.70M–-8%356,6767.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Bicycle Therapeutics company events

Bicycle Therapeutics filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Aug 20, 2026LeadershipCharles Swanton resigned as a Class II director of the Board of Directors of Bicycle Therapeutics plc, as a member of the Board’s committees and as a member of the Company’s Clinical Advisory Board, effective immediately. Filing
  3. Jul 30, 2026ResultsReleased financial results. Filing
  4. Jun 18, 2026VoteReported shareholder vote results. Filing
  5. May 21, 2026AnnouncementBicycle Therapeutics plc issued a press release announcing initial Duravelo-2 data for metastatic urothelial cancer at the 2026 American Society of Clinical Oncology Annual Meeting. Filing
  6. Apr 30, 2026ResultsReleased financial results. Filing
  7. Apr 20, 2026AnnouncementBicycle Therapeutics plc issued a press release providing updates on its nuzefatide pevedotin program and the Company’s EphA2 pipeline. Filing
  8. Mar 17, 2026LeadershipThe Company’s Board of Directors appointed Jennifer Perry, Pharm.D. as Chief Operating Officer, effective as of March 17, 2026. Filing
  9. Feb 3, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  10. Jan 12, 2026AnnouncementBicycle Therapeutics plc issued a press release announcing the Company’s recent accomplishments and outlining strategic priorities for 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Bicycle Therapeutics financials

Famous investors that hold BCYC

4 of the 50 well-known investors we track reported holding BCYC in their latest 13F filing. The largest position is Jim Simons's, worth $5.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.51M$5.6M0.0%-2%
Israel Englander · Millennium ManagementQ3 2026563,057$2.1M0.0%+2%
Ken Griffin · Citadel AdvisorsQ3 2026369,792$1.4M0.0%-33%
Steve Cohen · Point72 Asset ManagementQ3 2026119,392$439K0.0%-20%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BCYC in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A6.8%
Nov 16, 2026Armistice Capital, LLC13G/A6.8%

Questions about Bicycle Therapeutics Plc (BCYC) stock

Who owns the most BCYC stock?

The largest reported owner of Bicycle Therapeutics Plc (BCYC) is Baker Bros. Advisors LP, with 36.2% of the company. In total, 104 funds and institutions reported holding BCYC at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are BCYC insiders buying or selling?

In the last 12 months, BCYC insiders reported no open-market purchases and 48 sales worth $522K. The latest trade was on Oct 5, 2026. See every trade.

What is the short interest in BCYC?

As of Oct 30, 2026, 3.86M BCYC shares were sold short, up 11.7% from the report before. At the average daily volume of 460,266 shares, buying them all back would take about 8.4 trading days (days to cover). See the history.

Which famous investors hold BCYC?

4 of the 50 well-known investors we track reported BCYC in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $5.6M. See all holders.

Executive pay

Bicycle Therapeutics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, up 31% from $4.9M the year before. In the last 12 months, Bicycle Therapeutics's executives and directors bought no stock on the open market and sold $522K.

Chief executive, total pay$6.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.9MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.